Humana Inc. (NYSE:HUM) Shares Sold by Lindbrook Capital LLC

Lindbrook Capital LLC cut its holdings in Humana Inc. (NYSE:HUM) by 21.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,133 shares of the insurance provider’s stock after selling 306 shares during the quarter. Lindbrook Capital LLC’s holdings in Humana were worth $359,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HUM. Pzena Investment Management LLC boosted its holdings in shares of Humana by 538.7% during the second quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after purchasing an additional 1,955,375 shares during the last quarter. Ontario Teachers Pension Plan Board grew its holdings in Humana by 11,647.2% during the 1st quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock worth $367,342,000 after acquiring an additional 1,050,459 shares in the last quarter. Marshall Wace LLP increased its holdings in Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after buying an additional 774,085 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Humana by 261,025.1% during the third quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock worth $2,340,660,000 after purchasing an additional 738,701 shares during the last quarter. Finally, Steadfast Capital Management LP bought a new stake in shares of Humana in the 1st quarter worth approximately $158,813,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Performance

Humana stock opened at $288.12 on Friday. The stock has a market cap of $34.69 billion, a PE ratio of 25.52, a P/E/G ratio of 2.28 and a beta of 0.52. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $527.18. The business’s 50-day moving average price is $289.38 and its two-hundred day moving average price is $332.67.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, analysts expect that Humana Inc. will post 15.83 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio is currently 31.36%.

Analysts Set New Price Targets

HUM has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their price target on Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a report on Wednesday, August 21st. Jefferies Financial Group downgraded Humana from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $519.00 to $253.00 in a research note on Monday, October 7th. Wells Fargo & Company cut their price objective on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Humana from $349.00 to $250.00 and set a “hold” rating for the company in a report on Thursday, October 3rd. Finally, Piper Sandler lowered Humana from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $392.00 to $274.00 in a research report on Thursday, October 3rd. Twenty investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Humana currently has an average rating of “Hold” and an average price target of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.